Skip to main content

Advertisement

SpringerLink
Log in

Eradication of Helicobacter pylori Infection

  • Stomach and Duodenum (J Pisegna, Section Editor)
  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

Helicobacter pylori infects about 50 % of the world’s population, causing at a minimum chronic gastritis. A subset of infected patients will ultimately develop gastric or duodenal ulcer disease, gastric adenocarcinoma, or MALT (mucosa-associated lymphoid tissue) lymphoma. Eradication of H. pylori requires complex regimens that include acid suppression and multiple antibiotics. The efficacy of treatment using what were once considered standard regimens have declined in recent years, mainly due to widespread development of antibiotic resistance. Addition of bismuth to standard triple therapy regimens, use of alternate antibiotics, or development of alternative regimens using known therapies in novel combinations have improved treatment efficacy in specific populations, but overall success of eradication remains less than ideal. Novel regimens under investigation either in vivo or in vitro, involving increased acid suppression ideally with fewer antibiotics or development of non-antibiotic treatment targets, show promise for future therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;1(8390):1311–5.

    Article  CAS  PubMed  Google Scholar 

  2. Blaser MJ. Hypotheses on the pathogenesis and natural history of Helicobacter pylori-induced inflammation. Gastroenterology. 1992;102(2):720–7.

    Article  CAS  PubMed  Google Scholar 

  3. Nomura A, Stemmermann GN, Chyou PH, Kato I, Perez-Perez GI, Blaser MJ. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med. 1991;325(16):1132–6.

    Article  CAS  PubMed  Google Scholar 

  4. Parsonnet J. Gastric adenocarcinoma and Helicobacter pylori infection. Western J Med. 1994;161(1):60.

    CAS  Google Scholar 

  5. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991;325(16):1127–31.

    Article  CAS  PubMed  Google Scholar 

  6. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002;347(15):1175–86.

    Article  CAS  PubMed  Google Scholar 

  7. Infection with Helicobacter pylori In: Cancer IAfRo, editor. IARC monographs on the evaluation of the carcinogenic risk to humans-Schistosomes, liver flukes, and Helicobacter pylori. Lyon, France 1994. p. 177–240.

  8. Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO: classification of tumors of the digestive system. 4th ed. Geneva: IARC Press; 2010.

    Google Scholar 

  9. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2008;127(12):2893–917.

    Article  CAS  Google Scholar 

  10. Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane database of systematic reviews (Online). 2006(2):CD003840.

  11. Gisbert JP, Khorrami S, Carballo F, Calvet X, Gene E, Dominguez-Munoz JE. H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. Cochrane database of systematic reviews (Online). 2003(4):CD004062.

  12. Leodolter A, Kulig M, Brasch H, Meyer-Sabellek W, Willich SN, Malfertheiner P. A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer. Aliment Pharmacol Ther. 2001;15(12):1949–58.

    Article  CAS  PubMed  Google Scholar 

  13. Chen LT, Lin JT, Tai JJ, Chen GH, Yeh HZ, Yang SS, et al. Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma. J Natl Cancer Inst. 2005;97(18):1345–53.

    Article  CAS  PubMed  Google Scholar 

  14. Stathis A, Chini C, Bertoni F, Proserpio I, Capella C, Mazzucchelli L, et al. Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type. Ann Oncol. 2009;20(6):1086–93.

    Article  CAS  PubMed  Google Scholar 

  15. Wotherspoon AC, Doglioni C, Diss TC, Pan L, Moschini A, de Boni M, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet. 1993;342(8871):575–7.

    Article  CAS  PubMed  Google Scholar 

  16. Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA. 2004;291(2):187–94.

    Article  CAS  PubMed  Google Scholar 

  17. Tulassay Z, Stolte M, Engstrand L, Butruk E, Malfertheiner P, Dite P, et al. Twelve-month endoscopic and histological analysis following proton-pump inhibitor-based triple therapy in Helicobacter pylori-positive patients with gastric ulcers. Scand J Gastroenterol. 2010;45(9):1048–58.

    Article  CAS  PubMed  Google Scholar 

  18. Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter. 2007;12(4):275–8. doi:10.1111/j.1523-5378.2007.00518.x.

    Article  PubMed  Google Scholar 

  19. Kim SY, Choi DJ, Chung JW. Antibiotic treatment for Helicobacter pylori: is the end coming? World J Gastrointest Pharmacol Ther. 2015;6(4):183–98. doi:10.4292/wjgpt.v6.i4.183. Provides a helpful overview of worldwide antibiotic resistance patterns.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Teyssen S, Chari ST, Scheid J, Singer MV. Effect of repeated boluses of intravenous omeprazole and primed infusions of ranitidine on 24-hour intragastric pH in healthy human subjects. Dig Dis Sci. 1995;40(2):247–55.

    Article  CAS  PubMed  Google Scholar 

  21. Code CF. Defense mechanisms of the gastric mucosa. Scand J Gastroenterol Suppl. 1981;67:201–4.

    CAS  PubMed  Google Scholar 

  22. Henriksnas J, Phillipson M, Storm M, Engstrand L, Soleimani M, Holm L. Impaired mucus-bicarbonate barrier in Helicobacter pylori-infected mice. Am J Physiol. 2006;291(3):G396–403.

    Google Scholar 

  23. Baumgartner HK, Montrose MH. Regulated alkali secretion acts in tandem with unstirred layers to regulate mouse gastric surface pH. Gastroenterology. 2004;126(3):774–83.

    Article  CAS  PubMed  Google Scholar 

  24. Scott DR, Marcus EA, Wen Y, Oh J, Sachs G. Gene expression in vivo shows that Helicobacter pylori colonizes an acidic niche on the gastric surface. Proc Natl Acad Sci U S A. 2007;104(17):7235–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Larkin CJ, Watson RGP, Sloan JM, Stevenson M, Ardill JE, Buchanan D. Distribution of atrophy in Helicobacter pylori-infected subjects taking proton pump inhibitors. Scand J Gastroenterol. 2000;35(6):578–82.

    Article  CAS  PubMed  Google Scholar 

  26. Lee A, Dixon MF, Danon SJ, Kuipers E, Megraud F, Larsson H, et al. Local acid production and Helicobacter pylori: a unifying hypothesis of gastroduodenal disease. Eur J Gastroenterol Hepatol. 1995;7(5):461–5.

    CAS  PubMed  Google Scholar 

  27. Logan RP, Walker MM, Misiewicz JJ, Gummett PA, Karim QN, Baron JH. Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. Gut. 1995;36(1):12–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Mollenhauer-Rektorschek M, Hanauer G, Sachs G, Melchers K. Expression of UreI is required for intragastric transit and colonization of gerbil gastric mucosa by Helicobacter pylori. Res Microbiol. 2002;153(10):659–66.

    Article  CAS  PubMed  Google Scholar 

  29. Meyer-Rosberg K, Scott DR, Rex D, Melchers K, Sachs G. The effect of environmental pH on the proton motive force of Helicobacter pylori. Gastroenterology. 1996;111(4):886–900.

    Article  CAS  PubMed  Google Scholar 

  30. Marcus EA, Moshfegh AP, Sachs G, Scott DR. The periplasmic alpha-carbonic anhydrase activity of Helicobacter pylori is essential for acid acclimation. J Bacteriol. 2005;187(2):729–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Ma Z, Gong S, Richard H, Tucker DL, Conway T, Foster JW. GadE (YhiE) activates glutamate decarboxylase-dependent acid resistance in Escherichia coli K-12. Mol Microbiol. 2003;49(5):1309–20.

    Article  CAS  PubMed  Google Scholar 

  32. Scott DR, Marcus EA, Weeks DL, Lee A, Melchers K, Sachs G. Expression of the Helicobacter pylori ureI gene is required for acidic pH activation of cytoplasmic urease. Infect Immun. 2000;68(2):470–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Weeks DL, Eskandari S, Scott DR, Sachs G. A H+-gated urea channel: the link between Helicobacter pylori urease and gastric colonization. Sci (New York, NY). 2000;287(5452):482–5.

    Article  CAS  Google Scholar 

  34. Marcus EA, Sachs G, Wen Y, Feng J, Scott DR. Role of the Helicobacter pylori sensor kinase ArsS in protein trafficking and acid acclimation. J Bacteriol. 2012;194(20):5545–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Marcus EA, Inatomi N, Nagami GT, Sachs G, Scott DR. The effects of varying acidity on Helicobacter pylori growth and the bactericidal efficacy of ampicillin. Aliment Pharmacol Ther. 2012;36(10):972–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010;59(8):1143–53.

    Article  CAS  PubMed  Google Scholar 

  37. Molina-Infante J, Shiotani A. Practical aspects in choosing a Helicobacter pylori therapy. Gastroenterol Clin N Am. 2015;44(3):519–35. doi:10.1016/j.gtc.2015.05.004. A clearly written and rational guide explaining why different treatment regimens may be appropriate or less ideal for H. pylori infection in specific circumstances.

  38. Sugimoto M, Shirai N, Nishino M, Kodaira C, Uotani T, Yamade M, et al. Rabeprazole 10 mg q.d.s. decreases 24-h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype. Aliment Pharmacol Ther. 2012;36(7):627–34. doi:10.1111/apt.12014.

    Article  CAS  PubMed  Google Scholar 

  39. Gisbert JP, Gonzalez L, Calvet X, Garcia N, Lopez T, Roque M, et al. Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. Aliment Pharmacol Ther. 2000;14(10):1319–28.

    Article  CAS  PubMed  Google Scholar 

  40. Villoria A. Acid-related diseases: are higher doses of proton pump inhibitors more effective in the treatment of Helicobacter pylori infection? Gastroenterol Hepatol. 2008;31(8):546–7.

    Article  PubMed  Google Scholar 

  41. Calvet X, Garcia N, Lopez T, Gisbert JP, Gene E, Roque M. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther. 2000;14(5):603–9.

    Article  CAS  PubMed  Google Scholar 

  42. Ford A, Moayyedi P. How can the current strategies for Helicobacter pylori eradication therapy be improved? Can J Gastroenterol. 2003;17(Suppl B):36B–40B.

    Article  PubMed  Google Scholar 

  43. Fuccio L, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med. 2007;147(8):553–62.

    Article  PubMed  Google Scholar 

  44. Lind T, van Zanten VS, Unge P, Spiller R, Bayerdorffer E, O’Morain C, et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. Helicobacter. 1996;1(3):138–44.

    Article  CAS  PubMed  Google Scholar 

  45. Malfertheiner P, Megraud F, O’Morain C, Bell D, Bianchi Porro G, Deltenre M, et al. Current European concepts in the management of Helicobacter pylori infection—the Maastricht Consensus report. The European Helicobacter Pylori study group (EHPSG). Eur J Gastroenterol Hepatol. 1997;9(1):1–2.

    Article  CAS  PubMed  Google Scholar 

  46. Khalifa MM, Sharaf RR, Aziz RK. Helicobacter pylori: a poor man’s gut pathogen? Gut Pathog. 2010;2(1):2. doi:10.1186/1757-4749-2-2.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  47. Malfertheiner P, Megraud F, O’ Morain CA, Atherton J, Axon AT, Bazzoli F, et al. Management of Helicobacter pylori infection—the Maastricht IV/Florence consensus report. Gut. 2012;61(5):646–64.

    Article  CAS  PubMed  Google Scholar 

  48. Megraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut. 2004;53(9):1374–84. doi:10.1136/gut.2003.022111.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Webber MA, Piddock LJ. The importance of efflux pumps in bacterial antibiotic resistance. J Antimicrob Chemother. 2003;51(1):9–11.

    Article  CAS  PubMed  Google Scholar 

  50. McMahon BJ, Hennessy TW, Bensler JM, Bruden DL, Parkinson AJ, Morris JM, et al. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med. 2003;139(6):463–9.

    Article  PubMed  Google Scholar 

  51. Goodwin A, Kersulyte D, Sisson G, van Zanten VSJ, Berg DE, Hoffman PS. Metronidazole resistance in Helicobacter pylori is due to null mutations in a gene (rdxA) that encodes an oxygen-insensitive NADPH nitroreductase. Mol Microbiol. 1998;28(2):383–93.

    Article  CAS  PubMed  Google Scholar 

  52. Jenks PJ, Edwards DI. Metronidazole resistance in Helicobacter pylori. Int J Antimicrob Agents. 2002;19(1):1–7.

    Article  CAS  PubMed  Google Scholar 

  53. Chey WD, Wong BC. Practice parameters committee of the American College of G. American College of gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007;102(8):1808–25. doi:10.1111/j.1572-0241.2007.01393.x.

    Article  CAS  PubMed  Google Scholar 

  54. Megraud F, Lamouliatte H. Review article: the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther. 2003;17(11):1333–43.

    Article  CAS  PubMed  Google Scholar 

  55. Zhang W, Chen Q, Liang X, Liu W, Xiao S, Graham DY, et al. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy. Gut. 2015;64(11):1715–20. doi:10.1136/gutjnl-2015-309900.

    Article  CAS  PubMed  Google Scholar 

  56. Qureshi NN, Gallaher B, Schiller NL. Evolution of amoxicillin resistance of Helicobacter pylori in vitro: characterization of resistance mechanisms. Microb Drug Resist. 2014;20(6):509–16. doi:10.1089/mdr.2014.0019.

    Article  CAS  PubMed  Google Scholar 

  57. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther. 2007;26(3):343–57. doi:10.1111/j.1365-2036.2007.03386.x.

    Article  CAS  PubMed  Google Scholar 

  58. Cao Z, Chen Q, Zhang W, Liang X, Liao J, Liu W, et al. Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for Helicobacter pylori treatment failures: a randomized clinical trial. Scand J Gastroenterol. 2015;50(10):1185–90. doi:10.3109/00365521.2015.1037345.

    Article  CAS  PubMed  Google Scholar 

  59. Gisbert JP, Romano M, Gravina AG, Solis-Munoz P, Bermejo F, Molina-Infante J, et al. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. Aliment Pharmacol Ther. 2015;41(8):768–75. doi:10.1111/apt.13128.

    Article  CAS  PubMed  Google Scholar 

  60. Liao J, Zheng Q, Liang X, Zhang W, Sun Q, Liu W, et al. Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy. Helicobacter. 2013;18(5):373–7. doi:10.1111/hel.12052.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Sun Q, Liang X, Zheng Q, Liu W, Xiao S, Gu W, et al. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication. Helicobacter. 2010;15(3):233–8. doi:10.1111/j.1523-5378.2010.00758.x.

    Article  CAS  PubMed  Google Scholar 

  62. Ge R, Chen Z, Zhou Q. The actions of bismuth in the treatment of Helicobacter pylori infections: an update. Metallomics. 2012;4(3):239–43. doi:10.1039/c2mt00180b.

    Article  CAS  PubMed  Google Scholar 

  63. Lambert JR, Midolo P. The actions of bismuth in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 1997;11 Suppl 1:27–33.

    Article  PubMed  Google Scholar 

  64. Thomas F, Bialek B, Hensel R. Medical use of bismuth: the two sides of the coin. Clin Toxicol. 2012;S3(004):1–5. doi:10.4172/2161-0495.

    Google Scholar 

  65. Lambert JR, Borromeo J, Eaves ER, Hansky J, Korman MG. Efficacy of different dosage regimens of bismuth in eradicating Campylobacter pylori. Gastroenterology. 1988;94:A248.

    Article  Google Scholar 

  66. Marshall BJ, Valenzuela JE, McCallum RW, Dooley CP, Guerrant RL, Cohen H, et al. Bismuth subsalicylate suppression of Helicobacter pylori in nonulcer dyspepsia: a double-blind placebo-controlled trial. Dig Dis Sci. 1993;38(9):1674–80.

    Article  CAS  PubMed  Google Scholar 

  67. McNulty CA. Bismuth subsalicylate in the treatment of gastritis due to Campylobacter pylori. Rev Infect Dis. 1990;12 Suppl 1:S94–8.

    Article  PubMed  Google Scholar 

  68. Phillips RH, Whitehead MW, Lacey S, Champion M, Thompson RP, Powell JJ. Solubility, absorption, and anti-Helicobacter pylori activity of bismuth subnitrate and colloidal bismuth subcitrate: in vitro data do not predict in vivo efficacy. Helicobacter. 2000;5(3):176–82.

    Article  CAS  PubMed  Google Scholar 

  69. Armstrong JA, Wee SH, Goodwin CS, Wilson DH. Response of Campylobacter pyloridis to antibiotics, bismuth and an acid-reducing agent in vitro—an ultrastructural study. J Med Microbiol. 1987;24(4):343–50. doi:10.1099/00222615-24-4-343.

    Article  CAS  PubMed  Google Scholar 

  70. Marshall BJ, Armstrong JA, Francis GJ, Nokes NT, Wee SH. Antibacterial action of bismuth in relation to Campylobacter pyloridis colonization and gastritis. Digestion. 1987;37 Suppl 2:16–30.

    PubMed  Google Scholar 

  71. Marcus EA, Sachs G, Scott DR. Colloidal bismuth subcitrate impedes proton entry into Helicobacter pylori and increases the efficacy of growth-dependent antibiotics. Aliment Pharmacol Ther. 2015. doi:10.1111/apt.13346.

    Google Scholar 

  72. Just PM. Overview of the fluoroquinolone antibiotics. Pharmacotherapy. 1993;13(2 Pt 2):4S–17S.

    CAS  PubMed  Google Scholar 

  73. Cattoir V, Nectoux J, Lascols C, Deforges L, Delchier JC, Megraud F, et al. Update on fluoroquinolone resistance in Helicobacter pylori: new mutations leading to resistance and first description of a gyrA polymorphism associated with hypersusceptibility. Int J Antimicrob Agents. 2007;29(4):389–96. doi:10.1016/j.ijantimicag.2006.11.007.

    Article  CAS  PubMed  Google Scholar 

  74. Moore RA, Beckthold B, Wong S, Kureishi A, Bryan LE. Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin-resistant mutants of Helicobacter pylori. Antimicrob Agents Chemother. 1995;39(1):107–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Chuah SK, Tai WC, Hsu PI, Wu DC, Wu KL, Kuo CM, et al. The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump inhibitor treatment—a pilot study. Helicobacter. 2012;17(5):374–81. doi:10.1111/j.1523-5378.2012.00960.x.

    Article  CAS  PubMed  Google Scholar 

  76. Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016;43(4):514–33. doi:10.1111/apt.13497. Provides a comprehensive overview of antibiotic resistance mechanisms, how to test for antibiotic resistance, and how to target therapy based on these results.

    Article  CAS  PubMed  Google Scholar 

  77. Gerrits MM, de Zoete MR, Arents NL, Kuipers EJ, Kusters JG. 16S rRNA mutation-mediated tetracycline resistance in Helicobacter pylori. Antimicrob Agents Chemother. 2002;46(9):2996–3000.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Chi CH, Lin CY, Sheu BS, Yang HB, Huang AH, Wu JJ. Quadruple therapy containing amoxicillin and tetracycline is an effective regimen to rescue failed triple therapy by overcoming the antimicrobial resistance of Helicobacter pylori. Aliment Pharmacol Ther. 2003;18(3):347–53.

    Article  CAS  PubMed  Google Scholar 

  79. Delchier JC, Malfertheiner P, Thieroff-Ekerdt R. Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of Helicobacter pylori. Aliment Pharmacol Ther. 2014;40(2):171–7. doi:10.1111/apt.12808.

    Article  CAS  PubMed  Google Scholar 

  80. Laine L, Hunt R, El-Zimaity H, Nguyen B, Osato M, Spenard J. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol. 2003;98(3):562–7.

    Article  CAS  PubMed  Google Scholar 

  81. Malfertheiner P, Bazzoli F, Delchier JC, Celinski K, Giguere M, Riviere M, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet. 2011;377(9769):905–13. doi:10.1016/S0140-6736(11)60020-2.

    Article  CAS  PubMed  Google Scholar 

  82. O’Morain C, Borody T, Farley A, De Boer WA, Dallaire C, Schuman R, et al. Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study. Aliment Pharmacol Ther. 2003;17(3):415–20.

    Article  PubMed  Google Scholar 

  83. Muller N, Amiot A, Le Thuaut A, Bastuji-Garin S, Deforges L, Delchier JC. Rescue therapy with bismuth-containing quadruple therapy in patients infected with metronidazole-resistant Helicobacter pylori strains. Clin Res Hepatol Gastroenterol. 2016. doi:10.1016/j.clinre.2015.12.012.

    PubMed  Google Scholar 

  84. Heep M, Beck D, Bayerdorffer E, Lehn N. Rifampin and rifabutin resistance mechanism in Helicobacter pylori. Antimicrob Agents Chemother. 1999;43(6):1497–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  85. Heep M, Rieger U, Beck D, Lehn N. Mutations in the beginning of the rpoB gene can induce resistance to rifamycins in both Helicobacter pylori and Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2000;44(4):1075–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Borody TJ, Pang G, Wettstein AR, Clancy R, Herdman K, Surace R, et al. Efficacy and safety of rifabutin-containing ‘rescue therapy’ for resistant Helicobacter pylori infection. Aliment Pharmacol Ther. 2006;23(4):481–8. doi:10.1111/j.1365-2036.2006.02793.x.

    Article  CAS  PubMed  Google Scholar 

  87. Lim HC, Lee YJ, An B, Lee SW, Lee YC, Moon BS. Rifabutin-based high-dose proton-pump inhibitor and amoxicillin triple regimen as the rescue treatment for Helicobacter pylori. Helicobacter. 2014;19(6):455–61. doi:10.1111/hel.12147.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Gisbert JP, Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther. 2012;35(2):209–21. doi:10.1111/j.1365-2036.2011.04937.x.

    Article  CAS  PubMed  Google Scholar 

  89. Romano M, Cuomo A, Gravina AG, Miranda A, Iovene MR, Tiso A, et al. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. Gut. 2010;59(11):1465–70. doi:10.1136/gut.2010.215350.

    Article  CAS  PubMed  Google Scholar 

  90. Zullo A, Hassan C, Morini S, De Francesco V, Ierardi E, Panella C, et al. Sequential therapy for H. pylori: an ‘aberrant’ therapy ready for general use. Dig Liver Dis. 2004;36(12):852–3. author reply 3.

    Article  CAS  PubMed  Google Scholar 

  91. Liou JM, Chen CC, Chen MJ, Chen CC, Chang CY, Fang YJ, et al. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet. 2013;381(9862):205–13. doi:10.1016/S0140-6736(12)61579-7.

    Article  PubMed  Google Scholar 

  92. Gisbert JP, Calvet X, O’Connor A, Megraud F, O’Morain CA. Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol. 2010;44(5):313–25. doi:10.1097/MCG.0b013e3181c8a1a3.

    CAS  PubMed  Google Scholar 

  93. Liou JM, Chen CC, Lee YC, Chang CY, Wu JY, Bair MJ, et al. Systematic review with meta-analysis: 10- or 14-day sequential therapy vs. 14-day triple therapy in the first line treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 2016;43(4):470–81. doi:10.1111/apt.13495.

    Article  PubMed  Google Scholar 

  94. Graham DY, Shiotani A. Which therapy for Helicobacter pylori infection? Gastroenterology. 2012;143(1):10–2. doi:10.1053/j.gastro.2012.05.012.

    Article  PubMed  PubMed Central  Google Scholar 

  95. Essa AS, Kramer JR, Graham DY, Treiber G. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing “concomitant therapy” versus triple therapy for Helicobacter pylori eradication. Helicobacter. 2009;14(2):109–18. doi:10.1111/j.1523-5378.2009.00671.x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Georgopoulos S, Papastergiou V, Xirouchakis E, Laoudi F, Lisgos P, Spiliadi C, et al. Nonbismuth quadruple “concomitant” therapy versus standard triple therapy, both of the duration of 10 days, for first-line H. pylori eradication: a randomized trial. J Clin Gastroenterol. 2013;47(3):228–32. doi:10.1097/MCG.0b013e31826015b0.

    Article  PubMed  Google Scholar 

  97. Gisbert JP, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol. 2012;5:23–34. doi:10.2147/CEG.S25419.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol. 2014;12(2):177–86 e3. doi:10.1016/j.cgh.2013.05.028. Discussion e12-3.

    Article  PubMed  Google Scholar 

  99. Hsu PI, Wu DC, Wu JY, Graham DY. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter. 2011;16(2):139–45. doi:10.1111/j.1523-5378.2011.00828.x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Hsu PI, Lin PC, Graham DY. Hybrid therapy for Helicobacter pylori infection: a systemic review and meta-analysis. World J Gastroenterol. 2015;21(45):12954–62. doi:10.3748/wjg.v21.i45.12954.

    Article  PubMed  PubMed Central  Google Scholar 

  101. Wang B, Wang YH, Lv ZF, Xiong HF, Wang H, Yang Y, et al. Review: efficacy and safety of hybrid therapy for Helicobacter pylori infection: a systematic review and meta-analysis. Helicobacter. 2015;20(2):79–88. doi:10.1111/hel.12180.

    Article  PubMed  Google Scholar 

  102. Glupczynski Y, Megraud F, Lopez-Brea M, Andersen LP. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis. 2001;20(11):820–3.

    Article  CAS  PubMed  Google Scholar 

  103. Heep M, Kist M, Strobel S, Beck D, Lehn N. Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy. Eur J Clin Microbiol Infect Dis. 2000;19(7):538–41.

    Article  CAS  PubMed  Google Scholar 

  104. Meyer JM, Silliman NP, Wang W, Siepman NY, Sugg JE, Morris D, et al. Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993–1999. Ann Intern Med. 2002;136(1):13–24.

    Article  PubMed  Google Scholar 

  105. Graham KS, Malaty H, el-Zimaity HM, Genta RM, Cole RA, al-Assi MT, et al. Variability with omeprazole-amoxicillin combinations for treatment of Helicobacter pylori infection. Am J Gastroenterol. 1995;90(9):1415–8.

    CAS  PubMed  Google Scholar 

  106. Sjostedt S, Sagar M, Lindberg G, Wikstrom B, Nord CE, Seensalu R. Prolonged and profound acid inhibition is crucial in Helicobacter pylori treatment with a proton pump inhibitor combined with amoxicillin. Scand J Gastroenterol. 1998;33(1):39–43.

    Article  CAS  PubMed  Google Scholar 

  107. Yang JC, Wang HL, Chern HD, Shun CT, Lin BR, Lin CJ, et al. Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication. Pharmacotherapy. 2011;31(3):227–38. doi:10.1592/phco.31.3.227.

    Article  CAS  PubMed  Google Scholar 

  108. MacGowan AP, Bowker KE. Continuous infusion of beta-lactam antibiotics. Clin Pharmacokinet. 1998;35(5):391–402.

    Article  CAS  PubMed  Google Scholar 

  109. Midolo PD, Turnidge JD, Munckhof WJ. Is bactericidal activity of amoxicillin against Helicobacter pylori concentration dependent? Antimicrob Agents Chemother. 1996;40(5):1327–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  110. Yang JC, Lin CJ, Wang HL, Chen JD, Kao JY, Shun CT, et al. High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection. Clin Gastroenterol Hepatol. 2015;13(5):895–905 e5. doi:10.1016/j.cgh.2014.10.036. Offers promise for the future of therapy for H. pylori , with an option for decreased antibiotic use, although results are not currently generalizable worldwide.

  111. Sakurai Y, Mori Y, Okamoto H, Nishimura A, Komura E, Araki T, et al. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects-a randomised open-label cross-over study. Aliment Pharmacol Ther. 2015. doi:10.1111/apt.13325.

    Google Scholar 

  112. Inaba T, Iwamuro M, Toyokawa T, Okada H. Letter: promising results of Helicobacter pylori eradication with vonoprazan-based triple therapy after failure of proton pump inhibitor-based triple therapy. Aliment Pharmacol Ther. 2016;43(1):179–80. doi:10.1111/apt.13462.

    Article  CAS  PubMed  Google Scholar 

  113. Murakami KSY, Shiino M, Funao N, Nishimura A, Asaka M. A phase 3, double-blind study of a triple therapy with TAK-438, amoxicillin, and clarithromycin as first line eradication of H. pylori and a triple therapy with TAK-438, amoxicillin, and metronidazole as second line eradication of H. pylori. Gastroenterology. 2014;146 Suppl 5:740.

    Article  Google Scholar 

  114. Puscas I. Treatment of gastroduodenal ulcers with carbonic anhydrase inhibitors. Ann N Y Acad Sci. 1984;429:587–91.

    Article  CAS  PubMed  Google Scholar 

  115. Buzas GM. Carbonic anhydrase, acetazolamide and Helicobacter pylori infection. Helicobacter. 2005;10(5):444. doi:10.1111/j.1523-5378.2005.00353.x.

    Article  PubMed  Google Scholar 

  116. Shahidzadeh R, Opekun A, Shiotani A, Graham DY. Effect of the carbonic anhydrase inhibitor, acetazolamide, on Helicobacter pylori infection in vivo: a pilot study. Helicobacter. 2005;10(2):136–8. doi:10.1111/j.1523-5378.2005.00306.x.

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

The authors are supported by K08DK100661 (EAM), UCLA CDI (EAM), USVA 2I01BX001006 (GS), R01DK105156-01 (GS).

Author information

Authors and Affiliations

  1. Department of Pediatrics, DGSOM at UCLA, Los Angeles, CA, USA

    Elizabeth A. Marcus

  2. Department of Physiology, DGSOM at UCLA, Los Angeles, CA, USA

    George Sachs & David R. Scott

  3. Department of Medicine, DGSOM at UCLA, Los Angeles, CA, USA

    George Sachs

  4. VA GLAHS, 11301 Wilshire Blvd. Bldg 113 Rm 324, Los Angeles, CA, 90073, USA

    Elizabeth A. Marcus, George Sachs & David R. Scott

Authors
  1. Elizabeth A. Marcus
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. George Sachs
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David R. Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elizabeth A. Marcus.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Stomach and Duodenum

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Marcus, E.A., Sachs, G. & Scott, D.R. Eradication of Helicobacter pylori Infection. Curr Gastroenterol Rep 18, 33 (2016). https://doi.org/10.1007/s11894-016-0509-x

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11894-016-0509-x

Keywords

Search

Navigation